Biodesix Presenting Results From Three Studies at SITC Annual Meeting; Oral Poster Presentation, Two Additional Poster Presentations

Blood-Based Assays to Predict Response to Combination Checkpoint Blockade, High dose interleukin 2 (HDIL-2) in Melanoma

November 8, Boulder, Colorado…Three studies involving the development and validation of Biodesix’ blood-based proteomic tests, to aid in patient selection or predicting outcomes in the use of immunotherapies, will be presented this week at SITC’s 31^st Annual Meeting.

Oral Poster Presentation:

Date and Time: Saturday, November 12, 12:20-12:30 p.m. EDT

Abstract Title: A test identifying advanced melanoma patients with long survival outcomes on nivolumab shows potential for selection for benefit from combination checkpoint blockade

Location: Prince George’s Exhibition Hall AB, in the presentation area in the far back right of the hall

Presenting Author: Jeffrey Weber, M.D. Ph.D – New York University/Langone Medical Center

Additional Authors: Mario Sznol, Harriet Kluger, Ruth Halaban, Heinrich Roder, Joanna Roder, Senait Asmellash, Arni Steingrimsson, Shauna Blackmon, Ryan Sullivan

Poster Presentation:

Date and Time: Saturday, November 12 12:00 p.m. – 1:00 p.m.; Saturday, November 12 6:45 – 8:00 p.m. EDT

Title: Application of a test developed for prediction of response to high dose interleukin-2 (HDIL-2) and the BDX008 test for prediction of outcomes following checkpoint inhibitors to cohorts of patients treated with HDIL-2 or nivolumab

Poster Number/Location: 106

Authors:

Ryan J. Sullivan, Theodore Logan, Nikhil I. Khushalani, Kim Margolin, Henry Koon, Thomas Olencki, Thomas Hutson, Brendan Curti, Joanna Roder, Shauna Blackmon, Heinrich Roder, John Stewart, Asim Amin, Marc Ernstoff, Joseph Clark, Michael B. Atkins, Howard Kaufman, Jeffrey Sosman, Jeffrey Weber, David F. McDermott

Poster Presentation:

Date and Time: Friday, November 11 12:15 – 1:30 p.m.; Friday, November 11 6:15 – 7:30 p.m. EDT

Title: A test identifying advanced melanoma patients with long survival outcomes on nivolumab shows potential for selection for benefit from combination checkpoint blockade

Poster Number: 107

Authors: Jeffrey Weber, Mario Sznol, Harriet Kluger, Ruth Halaban, Heinrich Roder, Joanna Roder, Senait Asmellash, Arni Steingrimsson, Shauna Blackmon, Ryan Sullivan

Poster Presentation:

Date and Time: Saturday, November 12 12:00 p.m. – 1:00 p.m.; Saturday, November 12 6:45 – 8:00 p.m. EDT

Title: High Dose Interleukin 2 (HD IL-2) Select Trial in Melanoma: A tissue and blood collection protocol to identify predictive biomarkers of response to HD IL-2 in patients with advanced melanoma

Poster number: 444

Authors: Ryan J. Sullivan, Yujin Hoshida, Theodore Logan, Nikhil I. Khushalani, Anita Giobbie-Hurder, Kim Margolin, Johanna Roder, Rupal Bhatt, Henry Koon, Thomas Olencki, Thomas Hutson, Brendan Curti, Shauna Blackmon, James Mier, Heinrich Roder, John Stewart, Asim Amin, Marc Ernstoff, Joseph Clark, Michael B. Atkins, Howard Kaufman, Jeffrey Sosman, Sabina Signoretti, David F. McDermott

About Biodesix
Biodesix^® is a molecular diagnostics company advancing the development of innovative blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including the GeneStrat^® and VeriStrat^® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.